At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
ALZN Alzamend Neuro, Inc
Market Closed 05-03 16:00:00 EDT
0.7260
-0.0090
-1.22%
盘后0.7685
+0.0425+5.85%
16:19 EDT
High0.7400
Low0.7152
Vol18.97K
Open0.7350
D1 Closing0.7350
Amplitude3.37%
Mkt Cap4.99M
Tradable Cap3.51M
Total Shares6.87M
T/O13.83K
T/O Rate0.39%
Tradable Shares4.83M
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
Buy Rating Justified by Alzamend Neuro’s Promising Alzheimer’s Treatments and Attractive Valuation
Alzamend Neuro, Inc., an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002 stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease. Alzamend Neuro, Inc. was incorporated in 2016 and is headquartered in Atlanta, Georgia.